GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Other Long-Term Liabilities

Dianthus Therapeutics (Dianthus Therapeutics) Other Long-Term Liabilities : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Other Long-Term Liabilities?

Dianthus Therapeutics's other long-term liabilities for the quarter that ended in Mar. 2024 was $0.00 Mil.

Dianthus Therapeutics's quarterly other long-term liabilities increased from Sep. 2023 ($-0.00 Mil) to Dec. 2023 ($-0.00 Mil) and increased from Dec. 2023 ($-0.00 Mil) to Mar. 2024 ($0.00 Mil).

Dianthus Therapeutics's annual other long-term liabilities declined from Dec. 2021 ($21.35 Mil) to Dec. 2022 ($0.00 Mil) and declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).

Dianthus Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Dianthus Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Other Long-Term Liabilities Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Other Long-Term Liabilities
- - -

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Other Long-Term Liabilities Get a 7-Day Free Trial - - - - -

Dianthus Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Dianthus Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Other Long-Term Liabilities
Comparable Companies
SELB INZY IKNA MACK CBUS PSTX ALVR STOK TCRX ATXS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
87E:Germany
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Website
https://www.dianthustx.com
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023